A molecular informatics view on best practice in multi-parameter compound optimization

Drug Discovery Today

Volumn 16, Issue 13-14, 2011, Pages 555-568

  Lusher, Scott J ^a   McGuire, Ross ^a   Azevedo, Rita ^a   Boiten, Jan Willem ^a   Van Schaik, Rene C ^a   De Vlieg, Jacob ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ATAZANAVIR; BEXAROTENE; INDINAVIR; MONTELUKAST; NEVIRAPINE; OLOPATADINE; RITONAVIR; SAQUINAVIR; TERBINAFINE; TIROFIBAN;

COMPUTER MODEL; DRUG DESIGN; DRUG STRUCTURE; MEDICAL INFORMATICS; PROCESS OPTIMIZATION; REVIEW; TECHNOLOGY;

COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR;

EID: 79959715338     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.05.005     Document Type: Review

References (107)

1. D.E. Clark What has computer-aided molecular design ever done for drug discovery? Exp. Opin. Drug Discov. 1 2006 103 110
2. T. Wunberg Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits Drug Discov. Today 11 2006 175 180 (Pubitemid 43375969)
3. E. Perola An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs J. Med. Chem. 53 2010 2986 2997
4. P.D. Leeson, and B. Springthorpe The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discov. 6 2007 881 890 (Pubitemid 350042396)
5. E.H. Kerns, and L. Di Pharmaceutical profiling in drug discovery Drug Discov. Today 8 2003 316 323 (Pubitemid 36332223)
6. W.L. Jorgensen The many roles of computation in drug discovery Science 303 2004 1813 1818 (Pubitemid 38374866)
7. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715 (Pubitemid 39173511)
8. S.J.F. Macdonald, and P.W. Smith Lead optimization in 12 months? True confessions of a chemistry team Drug Discov. Today 6 2001 947 953 (Pubitemid 32799252)
9. S.P. Brown Healthy skepticism: assessing realistic model performance Drug Discov. Today 14 2009 420 427
10. D.K. Agrafiotis Advanced biological and chemical discovery (ABCD): centralizing discovery knowledge in an inherently decentralized world J. Chem. Inf. Model. 47 2007 1999 2014 (Pubitemid 350275069)
11. C.L. Waller Strategies to support drug discovery through integration of systems and data Drug Discov. Today 12 2007 634 639 (Pubitemid 47243705)
12. A. Rojnuckarin ArQiologist: an integrated decision support tool for lead optimization J. Chem. Inf. Model. 45 2005 2 9 (Pubitemid 40736950)
13. S.J. Cho ADAAPT: Amgen's data access analysis, and prediction tools J. Comp. Mol. Design. 20 2006 249 261 (Pubitemid 44317517)
14. T. Sander OSIRIS, an entirely in-house developed drug discovery informatics system J. Chem. Inf. Model. 49 2009 232 246
15. J.R. Proudfoot Drugs, leads, and drug-likeness: an analysis of some recently launched drugs Bioorg. Med. Chem. Lett. 12 2002 1647 1650 (Pubitemid 34569263)
16. H. Zhao, and Z. Guo Medicinal chemistry strategies in follow-on drug discovery Drug Discov. Today 14 2009 516 522
17. I.D. Kuntz The maximal affinity of ligands Proc. Natl. Acad. Sci. U. S. A. 96 1999 9997 10002 (Pubitemid 29422500)
18. C. Bissantz A medicinal chemist's guide to molecular interactions J. Med. Chem. 53 2010 5061 5084
19. R.S. Bohacek The art and practice of structure-based drug design: a molecular modeling perspective Med. Res. Rev. 16 1996 3 50 (Pubitemid 26037075)
20. P.J. Hajduk Fragment-based drug design: how big is too big? J Med. Chem. 49 2006 6972 6976 (Pubitemid 44885985)
21. D. Shigemizu Extraction and analysis of chemical modification patterns in drug development J. Chem. Inf. Model. 49 2009 1122 1129
22. G.M. Kesurü, and G.M. Makara The influence of lead discovery strategies on the properties of drug candidates Nat. Rev. Drug Discov. 8 2009 203 212
23. D.K. Agrafiotis Recent advances in chemoinformatics J. Chem. Inf. Model. 47 2007 1279 1293 (Pubitemid 47214446)
24. M. MacCoss, and T.A. Baillie Organic chemistry in drug discovery Science 303 2004 1810 1813 (Pubitemid 38374865)
25. M.S. Lajiness Assessment of the consistency of medicinal chemists in reviewing sets of compounds J. Med. Chem. 47 2004 4891 4896 (Pubitemid 39238264)
26. V. Schnecke, and J. Boström Computational chemistry-driven decision making in lead generation Drug Discov. Today 11 2006 43 50 (Pubitemid 43227851)
27. P.D. Leeson Drug-like properties: guiding principles for design - or chemical prejudice? Drug Discov. Today: Technol. 1 2004 189 195 (Pubitemid 40197566)
28. A.L. Hopkins Ligand efficiency: a useful metric for lead selection Drug Discov. Today 9 2004 430 431 (Pubitemid 38510559)
29. B.K. Shoichet Virtual screening of chemical libraries Nature 432 2004 862 865 (Pubitemid 40037142)
30. D.E. Clark What has virtual screening ever done for drug discovery? Exp. Opin. Drug Discov. 3 2008 841 851
31. G. Schneider Virtual screening: an endless staircase? Nat. Rev. Drug Discov. 9 2010 273 276
32. G. Klebe Lead identification in post-genomics: computers as a complementary alternative Drug Discov. Today: Technol. 1 2004 225 230 (Pubitemid 40197571)
33. F.L. Stahura, and J. Bajorath Virtual screening methods that complement HTS Combinat. Chem. High Throughput Screen 7 2004 259 269 (Pubitemid 38858880)
34. J. Bajorath Integration of virtual and high-throughput screening Nat. Rev. Drug Discov. 1 2002 882 894 (Pubitemid 37361583)
35. L.B. Akella, and D. DeCaprio Cheminformatics approaches to analyse diversity in compound screening libraries Curr. Opin. Chem. Biol. 14 2010 325 330
36. R. Macarron Critical review of the role of HTS in drug discovery Drug Discov. Today 11 2006 277 279
37. M. Stahl Integrating molecular design resources within modern drug discovery research: the Roche experience Drug Discov. Today 11 2006 326 333
38. D.M. Goldstein High-throughput kinase profiling as a platform for drug discovery Nat. Rev. Drug Discov. 7 2008 391 397 (Pubitemid 351619111)
39. M. Bredel, and E. Jacoby Chemogenomics: an emerging strategy for rapid target and drug discovery Nat. Rev. Genet. 5 2004 262 275 (Pubitemid 38435622)
40. E. Maréchal Chemogenomics: a discipline at the crossroad of high throughput technologies, biomarker research, combinatorial chemistry, genomics, cheminformatics, bioinformatics and artificial intelligence Combinat. Chem. High Throughput Screen 11 2008 583 586
41. C.J. Harris, and A.P. Stevens Chemogenomics: structuring the drug discovery process to gene families Drug Discov. Today 11 2006 880 888 (Pubitemid 44403186)
42. E. Jacoby Chemogenomics: drug discovery's panacea? Mol. BioSyst. 2 2006 218 220 (Pubitemid 43965634)
43. S.V. Frye Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era Chem. Biol. 6 1999 R3 R7
44. J. Duarte NUREBASE: database of nuclear hormone receptors Nucleic Acids Res. 30 2002 364 368 (Pubitemid 34679586)
45. F. Horn Calculating and harvesting biological data: the GPCRDB and NucleaRDB Nucleic Acids Res. 29 2001 346 349 (Pubitemid 32054489)
46. E. Bettler NRSAS: nuclear receptor structure analysis servers Nucleic Acids Res. 31 2003 3400 3403 (Pubitemid 37442167)
47. J.J.J. van Durme NRMD: nuclear receptor mutation database Nucleic Acids Res. 31 2003 331 333
48. S. Folkertsma The nuclear receptor ligand-binding domain: a family-based structure analysis Curr. Med. Chem. 12 2005 1001 1016 (Pubitemid 40667790)
49. D.L. Wheeler Database resources of the National Center for Biotechnology Information Nucleic Acids Res. 35 2007 D5 D12
50. K.P. Seiler A small-molecule screening and cheminformatics resource database Nucleic Acids Res. 36 2007 D351 D359
51. M. Olah WOMBAT: world of molecular bioactivity T.I. Oprea, Cheminformatics in Drug Discovery Vol. 23 2005 Wiley-VCH 249 272
52. T.I. Oprea, and A. Tropsha Target, chemical and bioactivity databases - integration is key Drug Discov. Today 3 2006 357 365 (Pubitemid 46158390)
53. M.R. Doddareddy Chemogenomics: looking at biology through the lens of chemistry Stat. Anal. Data Mining 2 2009 149 160
54. S. Senger, and A.R. Leach Chapter 11 SAR knowledge bases in drug discovery Annual Reports in Computational Chemistry Vol. 4 2008 Elsevier 203 216
55. Y. Zhou Large-scale annotation of small-molecule libraries using public databases J. Chem. Inf. Model. 47 2007 1386 1394 (Pubitemid 47210042)
56. G.V. Paolini Global mapping of pharmacological space Nat. Biotechnol. 24 2006 805 815 (Pubitemid 44086621)
57. J. Delaney Modelling iterative compound optimization using a self-avoiding walk Drug Discov. Today 14 2008 198 207
58. M. Wawer Data structures and computational tools for the extraction of SAR information from large compound sets Drug Discov. Today 15 2010 630 639
59. T.J. Howe Data reduction and representation in drug discovery Drug Discov. Today 12 2007 45 53 (Pubitemid 46014478)
60. A.L. Hopkins, and A. Polinsky Knowledge and intelligence in drug design Annu. Rep. Med. Chem. 41 2006 425 437
61. M.D. Segall, and A.T. Chadwick Making priors a priority J. Comp. Mol. Discov. 24 2010 957 960
62. A.T. Chadwick, and M.D. Segall Overcoming psychological barriers to good discovery decisions Drug Discov. Today 15 2010 561 569
63. J. Shimada Integrating computer-based de novo drug design and multidimensional filtering for desirable drugs Targets 1 2002 196 205 (Pubitemid 40432671)
64. A. Tiwari, and A.K.T. Sekhar Workflow based framework for life science informatics Computat. Biol. Chem. 31 2007 305 319 (Pubitemid 47531992)
65. D.K. Agrafiotis Multiobjective optimization of combinatorial libraries J. Comput. Mol. Design 16 2002 335 356 (Pubitemid 35414667)
66. V.J. Gillet Combinatorial library design using a multiobjective genetic algorithm J. Chem. Inf. Computat. Sci. 42 2002 375 385 (Pubitemid 35355312)
67. O. Nicolotti Multiobjective optimization in quantitative structure-activity relationships: deriving accurate and interpretable QSARs J. Med. Chem. 45 2002 5069 5080 (Pubitemid 35278703)
68. S. Ekins Towards a new age of virtual ADME/TOX and multidimensional drug discovery Mol. Divers. 5 2002 255 275
69. C.A. Nicolaou Molecular optimization using computational multi-objective methods Curr. Opin. Drug Discov. Dev. 10 2007 316 324 (Pubitemid 46800225)
70. G. Schneider, and K.-H. Baringhaus Molecular Design: Concepts and Applications 2008 Wiley
71. S. Ekins Evolving molecules using multi-objective optimization: applying to ADME/Tox Drug Discov. Today 15 2010 451 460
72. D.K. Agrafiotis Multiobjective optimization of combinatorial libraries J. Comp. Mol. Design 16 2002 335 356 (Pubitemid 35414667)
73. F. Dey, and A. Caflisch Fragment-based de novo ligand design by multiobjective evolutionary optimization J. Chem. Inf. Model. 48 2008 679 690 (Pubitemid 351535435)
74. T. Hoffmann The future of discovery chemistry: quo vadis? Academic to industrial - the maturation of medicinal chemistry to chemical biology Drug Discov. Today 15 2010 260 264
75. J. Bajorath Rational drug discovery revisited: interfacing experimental programs with bio- and chemo-informatics Drug Discov. Today 6 2001 989 995 (Pubitemid 32884420)
76. T.H. Davenport Human aspects of the management of drug discovery knowledge Drug Discov. Today: Technol. 2 2005 205 209 (Pubitemid 41511434)
77. S.W. Muchmore Cheminformatic tools for medicinal chemists J. Med. Chem. 53 2010 4830 4841
78. P. Gund Informatics and computation for drug discovery - specialist or mainstream tools? Curr. Opin. Drug Discov. Dev. 12 2009 337 338
79. J. Kirchmair The protein data bank (PDB), its related services and software tools as key components for in silico guided drug discovery J. Med. Chem. 51 2008 7021 7040
80. S. Andersson Making medicinal chemistry more effective - application of Lean Sigma to improve processes, speed and quality Drug Discov. Today 14 2009 598 604
81. D.E. Clark, and C.G. Newton Outsourcing lead optimisation - the quiet revolution Drug Discov. Today 9 2004 492 500 (Pubitemid 38626086)
82. A.M. Davis Limitations and lessons in the use of X-ray structural information in drug design Drug Discov. Today 13 2008 831 841
83. M. Congreve Recent developments in fragment-based drug discovery J. Med. Chem. 51 2008 3661 3680 (Pubitemid 351956496)
84. S.B. Shuker Discovering high affinity ligands for proteins: SAR by NMR Science 274 1996 1531 1534 (Pubitemid 26403929)
85. R. Law The multiple roles of computational chemistry in fragment-based drug design J. Comp. Mol. Design. 23 2009 459 473
86. D.C. Rees Fragment-based lead discovery Nat. Rev. Drug Discov. 3 2004 660 672
87. R.E. Hubbard Informatics and modeling challenges in fragment-based drug discovery Curr. Opin. Drug Discov. Dev. 10 2007 289 297 (Pubitemid 46800223)
88. P.J. Hajduk, and J. Greer A decade of fragment-based drug design: strategic advances and lessons learned Nat. Rev. Drug Discov. 6 2007 211 219 (Pubitemid 46344625)
89. H.O. Villar, and M.R. Hansen Computational techniques in fragment based drug discovery Curr. Topics Med. Chem. 7 2007 1509 1513 (Pubitemid 47618063)
90. G. Schneider, and U. Fechner Computer-based de novo design of drug-like molecules Nat. Rev. Drug Discov. 4 2005 649 663 (Pubitemid 41149759)
91. H. Mauser, and W. Guba Recent developments in de novo design and scaffold hopping Curr. Opin. Drug Discov. Dev. 11 2008 365 374 (Pubitemid 351572446)
92. C.A. Nicolaou De novo drug design using multiobjective evolutionary graphs J. Chem. Inf. Model. 49 2009 295 307
93. P.S. Kutchukian De novo design: balancing novelty and confined chemical space Exp. Opin. Drug Discov. 5 2010 789 812
94. K. Boda Structure and reaction based evaluation of synthetic accessibility J. Comp. Mol. Design. 21 2007 311 325 (Pubitemid 47054812)
95. S.B. Nabuurs A flexible approach to induced fit docking J. Med. Chem. 50 2007 6507 6518 (Pubitemid 350309091)
96. M. Rarey A fast flexible docking method using an incremental construction algorithm J. Mol. Biol. 261 1996 470 489 (Pubitemid 26335901)
97. H. Claussen Efficient molecular docking considering protein structure variations J. Mol. Biol. 308 2001 377 395 (Pubitemid 33043576)
98. L. Ridder, and M. Wagener SyGMa: combining expert knowledge and empirical scoring in the prediction of metabolites ChemMedChem 3 2008 821 832
99. M. Wagener, and J.P.M. Lommerse The quest for bioisosteric replacements J. Chem. Inf. Model. 46 2006 677 685
100. I. Ujvary BIOSTER - a database of structurally analogous compounds Pestic. Sci. 51 1997 92 95
101. T.I. Oprea Is there a difference between leads and drugs? A historical perspective J. Chem. Inf. Comput. Sci. 41 2001 1308 1315
102. W. Sneader Drug Prototypes and their Exploration 1996 John Wiley & Sons
103. M.M. Hann Molecular complexity and its impact on the probability of finding leads for drug discovery J. Chem. Inf. Comput. Sci. 41 2001 856 864
104. S. Vilar Medicinal Chemistry and the Molecular Operating Environment (MOE): application of QSAR and molecular docking to drug discovery Curr. Topics Med. Chem. 8 2008 1555 1572
105. J. Rahuel Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human rennin Chem. Biol. 7 2000 493 504 (Pubitemid 30466984)
106. A. Wlodawer, and J. Vondrasek Inhibitors of HIV-1 protease: a major success of structure-assisted drug design Annu. Rev. Biophys. Biomol. Struct. 27 1998 249 284 (Pubitemid 28286016)
107. G. Bold New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development J. Med. Chem. 41 1998 3387 3401 (Pubitemid 28406546)